Total Leishmania antigens with Poly(I:C) induce Th1 protective response.

Area of Science:

• Immunology
• Vaccinology
• Parasitology

Background:

• Leishmaniasis remains a significant global health concern, particularly in developing countries.
• Effective vaccines are crucial for controlling the spread of Leishmania infections.
• Current vaccine strategies face challenges in inducing robust and protective immune responses.

Purpose of the Study:

• To develop and evaluate a vaccine candidate for leishmaniasis.
• The vaccine is based on total Leishmania antigens (TLA) adjuvanted with polyinosinic-polycytidylic acid [Poly(I:C)].
• The aim is to induce a protective Th1 immune response against Leishmania infection.

Main Methods:

• Mice were vaccinated with two doses of TLA-Poly(I:C) subcutaneously.
• Humoral and cellular immune responses were assessed post-vaccination.
• Vaccine efficacy was evaluated by challenging mice with Leishmania amazonensis and measuring protective responses.

Main Results:

• TLA-Poly(I:C) vaccination induced high anti-Leishmania IgG titers with a notable increase in IgG2a subclass, indicating a Th1 bias.
• Cellular immune responses showed increased Interferon-gamma (IFN-γ) production and minimal Interleukin-4 (IL-4) levels.
• Vaccinated mice exhibited reduced footpad swelling, lower parasite load, and diminished histopathological damage.

Conclusions:

• The TLA-Poly(I:C) vaccine formulation is a promising candidate for preventing cutaneous leishmaniasis.
• This vaccine is cost-effective and simple to develop, making it suitable for developing countries.
• The induced Th1 immune response is key to the vaccine's protective efficacy against Leishmania.